Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
The FDA is beginning rulemaking to close the “adequate provision” loophole
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Subscribe To Our Newsletter & Stay Updated
